IDL Diagnostics (IDLDX) Q1 2025 earnings summary

Executive summary

• Sales increased by 19.6% compared to the same quarter last year, with strong growth in both oncology and bacteriology segments.

• Strategic initiatives included expanded international presence, key collaborations in Asia, and participation in major scientific conferences.

• The Board proposed a name change to IDL Diagnostics AB to better reflect the business and product portfolio.

• The company maintains a solid cash position and is focused on innovation and market expansion.

Financial highlights

• Net sales for Q1 2025 were KSEK 15,307, up from KSEK 12,803 year-over-year.

• Profit after financial items was KSEK -12,327, compared to KSEK -10,505 in Q1 2024, including goodwill amortization of KSEK 9,895.

• EBITDA for the quarter was KSEK -2,212, down from KSEK -209 year-over-year.

• Cash and cash equivalents at period end were KSEK 46,470, nearly unchanged from KSEK 46,347 a year earlier.

• Earnings per share before and after dilution were SEK -0.05, unchanged year-over-year.

Outlook and guidance

• The company anticipates continued growth, driven by the expanding cancer diagnostics market and increased demand for biomarkers.

• Focus remains on strengthening presence in existing markets, obtaining new market approvals, and developing next-generation diagnostics.